Innovent Biologics Inc., a leading biopharmaceutical company, has announced that the U.S. Food and Drug Administration (FDA) has approved their investigational new drug $(IND.AU)$ application for IBI3032, a novel oral GLP-1R agonist. This approval allows Innovent to commence a Phase 1 clinical trial for IBI3032, targeting the treatment of various conditions such as diabetes, hypertension, and obstructive sleep apnea. The trials are set to begin in the second half of 2025, conducted concurrently in China and the U.S. Innovent's development of IBI3032 represents a significant advancement in their cardiovascular and metabolic $(CVM)$ pipeline, with the potential for global therapeutic impact.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innovent Biologics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN43304) on August 05, 2025, and is solely responsible for the information contained therein.